Novo Nordisk lets Canadian patent expire

Generic versions of Ozempic entered the Canadian market after Novo Nordisk allowed its patent to expire, possibly due to failing to pay a $250 filing fee. The move raises questions about whether this was strategic corporate planning or an expensive oversight, as it allows generics to compete while potentially avoiding statutory price caps on patented drugs.